ReviewBioengineering & translational medicine2025
Advances in biosensors for diagnosis and monitoring of inflammatory bowel disease: A review.
Review in Bioengineering & translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Adhesion-Enhanced Engineered Probiotic for Prolonged Intestinal Retention and Calprotectin-Responsive IBD Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Abbreviated non-contrast magnetic resonance enterography for Crohn's disease: a reliability study.La Radiologia medica · 2026Article
- Biosensor-Based Detection of Calprotectin and Lactoferrin as Neutrophil-Derived Markers of Inflammatory Bowel Diseases: From Molecular Pathophysiology to Point-of-Care Platforms.International journal of molecular sciences · 2026Review
- Article
- Advances in biosensors for diagnosis and monitoring of inflammatory bowel disease: A review.Bioengineering & translational medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) encompasses a group of intestinal disorders, primarily Crohn's disease (CD) and ulcerative colitis (UC), characterized by chronic inflammation of the digestive tract. Despite extensive research, the etiology of IBD remains largely unknown, and its progression and prognosis are unpredictable, often involving uncontrolled disease behavior. Current diagnostic and monitoring techniques, such as endoscopy, scoring systems, computed tomography, and ultrasound, provide valuable tools for assessing and monitoring disease progression; but are often used in conjunction with biomarker testing to achieve rapid and accurate results. Recent advances in biosensors, which integrate biorecognition elements with signal transduction platforms, offer immense potential to improve IBD diagnostics by enabling real-time, precise, and non-invasive detection of biomarkers such as C-reactive protein, calprotectin, and cytokines. This review examines existing IBD diagnostic techniques, their limitations, and the emerging role of biosensors in addressing these challenges. It explores the development of electrochemical and optical biosensors, highlights the key biomarkers utilized in these technologies, and identifies challenges and future opportunities for advancing next-generation biosensors for IBD diagnostics and monitoring. These innovations hold promise for enhancing IBD diagnosis, monitoring, and personalized disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.